|
|
 |
ALBUMIN HUMAN Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$798.00 |
|
|
 |
ALGINIC ACID Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
AMMONIA Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
AMMONIO METHACRYLATE COPOLYMER TYPE B Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ALPHA-TOCOPHEROL Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$798.00 |
|
|
 |
AMMONIO METHACRYLATE COPOLYMER TYPE A Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$798.00 |
|
|
 |
AKLIEF Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ACTOPLUS MET Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|